KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
-
Patient-Reported Anxiety Impacts Utilization of Injectable On-demand Treatment of Hereditary Angioedema Attacks:
Cristine Radojicic ,Autumn Burnette ,Sally van Kooten ,Neil Malloy ,Markus Heckmann ,Hilary Longhurst . Results shared as an e-Poster Presentation onFriday, October 25 at2:00pm ET , Monitor 20, Exhibit Hall A. -
On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebetralstat: Pooled Analysis from KONFIDENT and KONFIDENT-S: Emel Aygören-Pürsün,
Jonathan A. Bernstein ,William R. Lumry ,Paul K. Audhya ,James Hao ,Michael D. Smith ,Christopher M. Yea ,Marc A. Riedl . Results shared as an e-Poster Presentation onFriday, October 25 at5:00pm ET , Monitor 20, Exhibit Hall A. -
Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial:
William R. Lumry ,Danny M. Cohn ,Jonathan A. Bernstein ,Paul K. Audhya ,James Hao ,Michael D. Smith ,Christopher M. Yea ,Marc A. Riedl . Results shared as an e-Poster Presentation onFriday, October 25 at5:00pm ET , Monitor 19, Exhibit Hall A. -
Indirect treatment comparison of oral sebetralstat and intravenous rhC1-INH as on-demand treatments for hereditary angioedema:
H. Henry Li ,Markus Magerl ,Timothy Craig ,Michael E. Manning ,Noemi Hummel ,Alice Wang ,Paul K. Audhya ,Jonathan A. Bernstein . Results shared as an e-Poster Presentation onFriday, October 25 at5:15pm ET , Monitor 19, Exhibit Hall A. -
Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial:
Timothy J. Craig ,Jonathan A. Bernstein ,Hilary Longhurst ,James Hao ,Michael D. Smith ,Paul K. Audhya ,Christopher M. Yea ,Marcus Maurer . Results shared as an e-Poster Presentation onFriday, October 25 at5:30pm ET , Monitor 19, Exhibit Hall A.
Links to all posters and presentations can be found on the
About Sebetralstat
Discovered and developed entirely by the scientific team at
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the location affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.
About
For more information about
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018974820/en/
Vice President, Corporate Affairs
(617) 448-0281
jsnyder@kalvista.com
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: